Lung x-ray

Phase III Asthma Study

1 minute read

Published: January 10th, 2023

Phastar was engaged to rescue another CROs reporting of a large phase III study in mild asthmatics to evaluate the efficacy and safety of the experimental compound. With a primary objective to prove superiority in asthma control, analyses consisted of a complex primary endpoint and a broad range of secondary endpoints which are typically observed in respiratory.

Complete the form below to read the full case study

Related articles

From Rescue Study to Strategic Partnership: Accelerating Regulatory Submission Through Reliable Statistical Delivery

From Rescue Study to Strategic Partnership: Accelerating Regulatory Submission Through Reliable Statistical Delivery

November 16th, 2026 1 minute read

When clinical development programs face quality concerns, resource shortages, or submission risks, sponsors need a pa...

Turning a Failed Bioequivalence Study into a Successful Regulatory Outcome 

Turning a Failed Bioequivalence Study into a Successful Regulatory Outcome 

November 16th, 2026 1 minute read

When a bioequivalence study fails to meet regulatory criteria, understanding why is critical for successful developme...

Independent DMC Support and Interim Analysis for an ALS Clinical Trial 

Independent DMC Support and Interim Analysis for an ALS Clinical Trial 

November 16th, 2026 1 minute read

Data Monitoring Committees play a vital role in safeguarding patient safety and supporting informed decision-making t...